Skip to main content
Top
Published in: International Urology and Nephrology 7/2015

01-07-2015 | Nephrology - Original Paper

Risk factors for severe hypocalcemia after parathyroidectomy in prevalent dialysis patients with secondary hyperparathyroidism

Authors: Wan-Chuan Tsai, Yu-Sen Peng, Yen-Ling Chiu, Hon-Yen Wu, Mei-Fen Pai, Shih-Ping Hsu, Ju-Yeh Yang, Kuei-Ting Tung, Hung-Yuan Chen

Published in: International Urology and Nephrology | Issue 7/2015

Login to get access

Abstract

Purpose

Hypocalcemia is one of the common complications after parathyroidectomy (PTX). Severe hypocalcemia (SH) can lead to tetany, cardiac arrhythmia and even sudden death. However, predictors for the development of SH in patients with secondary hyperparathyroidism demonstrated in some small-scale studies with a limited sample size remain inconclusive.

Methods

A retrospective chart review of 420 consecutive dialysis patients who underwent PTX during a 12-year period was performed. We checked serum levels of calcium (Ca), phosphorus (P), alkaline phosphatase (ALP) and intact parathyroid hormone (iPTH) for three consecutive days postoperatively. SH was defined as the minimum values of serum calcium lower than 1.875 mmol/L (7.5 mg/dL) within 3 days after operation.

Results

The mean (±SD) age of our study population was 53 ± 12 years, and more than half (57 %) were female. SH occurred in 37 % of the patients after PTX. Using a multivariate stepwise logistic regression analysis, lower preoperative levels of Ca (odds ratio 0.69, 95 % CI 0.60–0.79, P < 0.001), higher preoperative levels of iPTH (odds ratio 1.04, 95 % CI 1.00–1.07, P = 0.048), P (odds ratio 2.43, 95 % CI 1.49–3.95, P < 0.001) and ALP (odds ratio 1.08, 95 % CI 1.05–1.11, P < 0.001) were found to be independent predictors of occurrence of SH following PTX.

Conclusions

The readily obtainable preoperative laboratory parameters including Ca, iPTH, P, and ALP will allow identification of a subgroup of patients who are at greater risk for the development of SH following PTX.
Literature
1.
go back to reference Tsai WC, Peng YS, Yang JY, Hsu SP, Wu HY, Pai MF, Chang JF, Chen HY (2013) Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience. Blood Purif 36(2):116–121. doi:10.1159/000353415 PubMedCrossRef Tsai WC, Peng YS, Yang JY, Hsu SP, Wu HY, Pai MF, Chang JF, Chen HY (2013) Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience. Blood Purif 36(2):116–121. doi:10.​1159/​000353415 PubMedCrossRef
3.
go back to reference Sharma J, Raggi P, Kutner N, Bailey J, Zhang R, Huang Y, Herzog CA, Weber C (2012) Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg 214(4):400–407; discussion 407–408. doi:10.1016/j.jamcollsurg.2011.12.046 Sharma J, Raggi P, Kutner N, Bailey J, Zhang R, Huang Y, Herzog CA, Weber C (2012) Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg 214(4):400–407; discussion 407–408. doi:10.​1016/​j.​jamcollsurg.​2011.​12.​046
4.
go back to reference Mittendorf EA, Merlino JI, McHenry CR (2004) Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg 70(2):114–119; discussion 119–120 Mittendorf EA, Merlino JI, McHenry CR (2004) Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg 70(2):114–119; discussion 119–120
6.
go back to reference Strickland PL, Recabaren J (2002) Are preoperative serum calcium, parathyroid hormone, and adenoma weight predictive of postoperative hypocalcemia? Am Surg 68(12):1080–1082PubMed Strickland PL, Recabaren J (2002) Are preoperative serum calcium, parathyroid hormone, and adenoma weight predictive of postoperative hypocalcemia? Am Surg 68(12):1080–1082PubMed
7.
go back to reference Viaene L, Evenepoel P, Bammens B, Claes K, Kuypers D, Vanrenterghem Y (2008) Calcium requirements after parathyroidectomy in patients with refractory secondary hyperparathyroidism. Nephron Clin Pract 110(2):c80–c85. doi:10.1159/000151722 PubMedCrossRef Viaene L, Evenepoel P, Bammens B, Claes K, Kuypers D, Vanrenterghem Y (2008) Calcium requirements after parathyroidectomy in patients with refractory secondary hyperparathyroidism. Nephron Clin Pract 110(2):c80–c85. doi:10.​1159/​000151722 PubMedCrossRef
9.
go back to reference Brasier AR, Nussbaum SR (1988) Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 84(4):654–660PubMedCrossRef Brasier AR, Nussbaum SR (1988) Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 84(4):654–660PubMedCrossRef
10.
go back to reference Denda M, Finch J, Slatopolsky E (1996) Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28(4):596–602PubMedCrossRef Denda M, Finch J, Slatopolsky E (1996) Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28(4):596–602PubMedCrossRef
11.
go back to reference Streja E, Lau WL, Goldstein L, Sim JJ, Molnar MZ, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K (2013) Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney Intern Suppl 3(5):462–468. doi:10.1038/kisup.2013.96 CrossRef Streja E, Lau WL, Goldstein L, Sim JJ, Molnar MZ, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K (2013) Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney Intern Suppl 3(5):462–468. doi:10.​1038/​kisup.​2013.​96 CrossRef
Metadata
Title
Risk factors for severe hypocalcemia after parathyroidectomy in prevalent dialysis patients with secondary hyperparathyroidism
Authors
Wan-Chuan Tsai
Yu-Sen Peng
Yen-Ling Chiu
Hon-Yen Wu
Mei-Fen Pai
Shih-Ping Hsu
Ju-Yeh Yang
Kuei-Ting Tung
Hung-Yuan Chen
Publication date
01-07-2015
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 7/2015
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-015-1016-y

Other articles of this Issue 7/2015

International Urology and Nephrology 7/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.